Characteristics of the 16 patients who received neratinib (N, %)a
| Age, years | |
| Median (range) | 58 (31–74) |
| Race | |
| White/African American/Asian | 13 (81%)/1 (6%)/2 (13%) |
| ECOG PS | |
| 0/1/2 | 9 (56%)/7 (44%)/0 (0%) |
| Menopausal status | |
| Pre-/postmenopausal | 2 (12%)/14(88%) |
| Histology | |
| Ductal/lobular | 11 (67%)/5 (31.3%) |
| Hormone receptor status | |
| ER+PR+/ER+PR−/ER−PR−HER2− | 7 (44%)/8 (50%)/1 (6%) |
| HER2 status | |
| Nonamplified/amplified | 16 (100%)/0 (0%) |
| Evaluable disease by RECIST | |
| Measurable/nonmeasurable | 13 (81%)/3 (19%) |
| Disease magnitude | |
| Visceral/nonvisceral | 11 (69%)/5 (31%) |
| Prior number of metastatic regimens | |
| Any/endocrine/chemo (median, range) | 3 (2–10)/2 (0–3)/2 (0–6) |
| Reason off study | |
| Adverse event/progressive disease | 1 (6%)/15 (94%) |
| Age, years | |
| Median (range) | 58 (31–74) |
| Race | |
| White/African American/Asian | 13 (81%)/1 (6%)/2 (13%) |
| ECOG PS | |
| 0/1/2 | 9 (56%)/7 (44%)/0 (0%) |
| Menopausal status | |
| Pre-/postmenopausal | 2 (12%)/14(88%) |
| Histology | |
| Ductal/lobular | 11 (67%)/5 (31.3%) |
| Hormone receptor status | |
| ER+PR+/ER+PR−/ER−PR−HER2− | 7 (44%)/8 (50%)/1 (6%) |
| HER2 status | |
| Nonamplified/amplified | 16 (100%)/0 (0%) |
| Evaluable disease by RECIST | |
| Measurable/nonmeasurable | 13 (81%)/3 (19%) |
| Disease magnitude | |
| Visceral/nonvisceral | 11 (69%)/5 (31%) |
| Prior number of metastatic regimens | |
| Any/endocrine/chemo (median, range) | 3 (2–10)/2 (0–3)/2 (0–6) |
| Reason off study | |
| Adverse event/progressive disease | 1 (6%)/15 (94%) |
aUnless otherwise specified.